Brand Intelligence Graph
Company Overview
About SpliceBio
SpliceBio is a gene therapy company whose protein trans-splicing platform overcomes the 4.7-kilobase cargo limit of adeno-associated viral (AAV) vectors — the primary delivery vehicle for gene therapy — unlocking treatments for large-gene diseases previously untreatable. The company raised $135 million in Series B financing co-led by Sanofi Ventures and EQT Life Sciences in June 2025, and dosed its first patient in Phase 1/2 Part B for SB-007 in Stargardt disease in January 2026.
Business Model & Competitive Advantage
The AAV cargo limit has been a fundamental constraint in gene therapy since the field's inception: genes larger than 4.7 kilobases cannot fit inside a standard AAV capsid, excluding conditions like Stargardt disease (ABCA4, 6.8kb), Usher syndrome (USH2A, 15.6kb), and many rare neurological diseases from gene therapy treatment. SpliceBio's trans-splicing approach splits the gene across two AAV vectors and uses engineered intein proteins to stitch the protein back together inside the cell — effectively doubling the gene therapy cargo capacity.
Competitive Landscape 2025–2026
Sanofi's direct Ventures arm investment is strategically significant: Sanofi has one of the world's largest rare disease and gene therapy portfolios, and co-leading the SpliceBio Series B signals active interest in trans-splicing for programs in its pipeline. The Stargardt Phase 1/2 data from 2026 will be the first clinical validation of protein trans-splicing technology in humans.
Key Differentiators
Emerging Innovator
SpliceBio is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare SpliceBio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from SpliceBio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim SpliceBio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention SpliceBio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →